Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Capricor Therapeutics, Inc. - Common Stock
(NQ:
CAPR
)
23.99
-0.80 (-3.23%)
Streaming Delayed Price
Updated: 9:46 AM EST, Jan 15, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Capricor Therapeutics, Inc. - Common Stock
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Capricor Therapeutics Cell Therapy Goes Under Priority FDA Review For Duchenne Associated-Heart Condition
↗
March 04, 2025
FDA grants Priority Review to Capricor's deramiocel for Duchenne cardiomyopathy, setting an August 2025 decision date with no identified review issues.
Via
Benzinga
8 Health Care Stocks Whale Activity In Today's Session
↗
January 08, 2025
Via
Benzinga
Beyond The Numbers: 7 Analysts Discuss Capricor Therapeutics Stock
↗
January 02, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 05, 2024
Via
Benzinga
America's Car-Mart Posts Upbeat Sales, Joins Methode Electronics, Verint Systems, Brown-Forman And Other Big Stocks Moving Higher On Thursday
↗
December 05, 2024
Via
Benzinga
Decoding 12 Analyst Evaluations For Capricor Therapeutics
↗
November 14, 2024
Via
Benzinga
Earnings Scheduled For November 13, 2024
↗
November 13, 2024
Via
Benzinga
Earnings Preview For Capricor Therapeutics
↗
November 12, 2024
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $6,800 Today
↗
October 11, 2024
Via
Benzinga
Why Verint Systems Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
↗
December 05, 2024
Via
Benzinga
Space, Biotech, And More: Today’s Hottest Stocks To Watch
↗
November 14, 2024
Today’s macro environment reflects a strong risk-on sentiment, fueled by a notable rally in Bitcoin, which has surged past the $90,000 threshold.
Via
Talk Markets
Why Capricor Therapeutics (CAPR) Shares Are Trading Lower
↗
October 17, 2024
Capricor Therapeutics shares are trading lower by 2.7% during Thursday's session. The company earlier commenced its public offering of common stock.
Via
Benzinga
CSX Posts Weak Earnings, Joins Lucid Group, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
October 17, 2024
Via
Benzinga
Forecasting The Future: 9 Analyst Projections For Capricor Therapeutics
↗
October 09, 2024
Via
Benzinga
Here's How Much $100 Invested In Capricor Therapeutics 5 Years Ago Would Be Worth Today
↗
September 30, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
October 16, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
↗
October 16, 2024
Via
Benzinga
Capricor Therapeutics Says Duchenne Muscular Dystrophy Candidate Shows Sustained Cardiac, Skeletal Benefits After 3 Years
↗
October 11, 2024
Capricor Therapeutics announced promising 3-year results from its HOPE-2 extension study for deramiocel in treating Duchenne muscular dystrophy, showing significant cardiac and motor function...
Via
Benzinga
Fastenal Posts Upbeat Earnings, Joins Wells Fargo, JPMorgan And Other Big Stocks Moving Higher On Friday
↗
October 11, 2024
Via
Benzinga
PepsiCo, DocuSign, Robinhood And Other Big Stocks Moving Higher On Tuesday
↗
October 08, 2024
Via
Benzinga
MarketBeat Week in Review – 9/30 - 10/4
October 05, 2024
A strong jobs report and a temporary settlement of the port strike lifted stocks but inflation and earnings data could set investors up for more volatility
Via
MarketBeat
Topics
Economy
12 Health Care Stocks Moving In Friday's Intraday Session
↗
October 04, 2024
Via
Benzinga
Apogee Enterprises Posts Upbeat Earnings, Joins Frontier Group, JetBlue Airways And Other Big Stocks Moving Higher On Friday
↗
October 04, 2024
Via
Benzinga
Nike Reports Weak Sales, Joins Lamb Weston And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
↗
October 02, 2024
Via
Benzinga
IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
October 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
↗
September 30, 2024
Via
Benzinga
Prime Medicine, MINISO Group, Li Auto, Weibo And Other Big Stocks Moving Higher On Monday
↗
September 30, 2024
Via
Benzinga
Capricor Therapeutics Is Up Over 100%, Could Rise Even Higher
September 30, 2024
Capricor Therapeutics Inc. (NASDAQ: CAPR) is a biotechnology firm focused on developing cell and exosome-based treatments for rare diseases like iomyopathy
Via
MarketBeat
Dow Tumbles Over 200 Points; CERo Therapeutics Shares Jump
↗
September 25, 2024
Via
Benzinga
Topics
Stocks
Crude Oil Down Over 1%; Stitch Fix Shares Plummet
↗
September 25, 2024
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today